Why damaged hip cartilage stays damaged

Most patients reach this point having heard the same phrase from a scan report or a clinic appointment: the cartilage in your hip is worn and will not grow back. That is not pessimism — it is biology.

Hyaline cartilage, the smooth tissue lining the ball and socket of the hip, contains no blood vessels. Where most tissues can mount a repair response after injury — recruiting inflammatory cells, laying down new matrix, closing a wound — cartilage cannot. There is no local blood supply to trigger that cascade. Minor surface damage therefore persists, and under the repeated compressive loads the hip bears with every step, the compromised matrix breaks down further. Thinning accelerates. Once the protective layer is sufficiently reduced, bone begins to meet bone.

This biology is precisely what makes the treatment window matter. The joint cannot wait for endogenous healing that will not arrive. Instead, introducing an exogenous repair substrate — a scaffold the body's own cells can populate and gradually remodel — offers a means of intervening in that deterioration before the window closes.

What ChondroFiller is and how it works in a hip joint

ChondroFiller is a CE-marked Class III medical device — a purified Type I collagen scaffold with more than 20,000 implantations across its clinical history since receiving its injectable CE mark in 2013.

The collagen is extracted using a weak-acid process rather than the enzyme-digestion method common in commercial collagens. That distinction matters biologically: acid extraction preserves the telopeptide regions (short protein sequences at each end of the collagen molecule) that enzyme methods remove. Intact telopeptides allow the fibres to cross-link in the way native tissue does, producing a scaffold that more closely resembles the joint's own extracellular matrix.

Once placed into the hip under ultrasound guidance, the liquid gels within minutes into a stable, three-dimensional scaffold at the worn articular surface. The mechanism that follows is acellular matrix-induced chondrogenesis: progenitor cells from the surrounding synovium and subchondral bone migrate into the scaffold, mature, and begin building cartilage matrix. As that repair tissue forms, the scaffold gradually biodegrades — replaced rather than remaining permanently in the joint.

Two common comparators clarify what ChondroFiller is not. Hyaluronic acid is a lubricant, cleared from the joint within weeks; it does not provide a structural scaffold or support tissue repair. Polyacrylamide hydrogels are permanent, non-biodegradable fillers that cushion but do not promote repair. ChondroFiller, by contrast, acts as an additive biological layer that supports the body's own repair processes — applicable to both discrete focal defects and the more diffuse articular wear of advanced hip osteoarthritis.

The ultrasound-guided injection appointment

For most patients, the appointment itself is the clearest departure from what they expected. There is no theatre booking, no general anaesthetic, and no surgical consent pathway — ChondroFiller is delivered as an outpatient injection under ultrasound guidance, typically with local anaesthesia only.

On the day, the sequence is straightforward. A clinical consultation confirms the plan, in-room ultrasound imaging identifies the target site within the hip joint, and the 2.3 mL collagen scaffold is placed under real-time image guidance into the fluid joint space. Because the hip remains in its natural fluid environment throughout, none of the dry-field preparation that arthroscopic implantation requires is needed — no operating theatre, no portals, no dry-joint technique. Intravenous antibiotic cover is included as standard. A six-week follow-up appointment is part of the package.

For patients comparing this with arthroscopic cartilage surgery — which demands a dry joint, spinal or general anaesthesia, and a theatre admission — the distinction in recovery burden is substantial. Injection-route patients are not post-operative; downtime is considerably less.

Guide cost starts from £3,000 per box, covering consultation, ultrasound, the product, the injection procedure, antibiotic cover, and the follow-up appointment. The treating clinic confirms the exact figure at assessment, as some presentations — particularly those requiring combination therapy — involve a different price point.

Which hip patients are suitable

The phrase 'too far gone' is one of the most common things patients bring into an assessment — and it is rarely the end of the conversation. Suitability for ChondroFiller injection is evaluated across four clinical lenses: the physics of the joint (how load is distributed and whether mechanics are workable), the chemistry of the joint environment (whether the biological conditions support scaffold integration), the patient's biology (their capacity for cellular repair), and timing (the stage and trajectory of degeneration). No single lens rules a patient out on its own.

Age is not a barrier. Neither is bone-on-bone contact on imaging — a finding that often leads patients to assume surgery or replacement is the only remaining option. Because the injectable pathway places ChondroFiller as an additive biological layer over worn articular surfaces, it is applicable to the diffuse, advanced wear of Kellgren-Lawrence Grade III and IV osteoarthritis, not only to the isolated focal defects with clean healthy borders that arthroscopic techniques depend on. Hip is one of the three joints most frequently treated with ChondroFiller injection — alongside knee and ankle — reflecting genuine clinical experience rather than a novel or experimental application.

In the most advanced presentations, the assessment may consider whether a second agent could address a different aspect of the joint environment. Arthrosamid, for instance, targets the synovial lining rather than the articular surface and acts as a hydrogel cushion — a mechanically distinct role from ChondroFiller's regenerative scaffold function. Autologous mesenchymal stem cells may be considered as a further biological adjunct in selected cases. Whether either is appropriate is determined at assessment, not assumed.

What the outcome evidence shows

Published hip-specific evidence centres on Perez-Carro et al. (2021), a study that used the modified Harris Hip Score (mHHS) as its primary patient-reported outcome. Data from that series indicate an improvement of approximately 30 points on the mHHS — a gain that substantially clears the threshold for clinical significance in hip function. For presentations where exact figures inform shared decision-making, the original paper is the primary reference; what the published record establishes is a consistent, meaningful functional improvement following ChondroFiller injection in the hip.

For structural corroboration, MRI-based MOCART scoring provides an independent signal. Across European studies, MOCART scores in ChondroFiller-treated joints range from 81.6 to 84.3, reflecting greater than 80% defect fill and good integration with native tissue. The trajectory matters as much as the endpoint: MOCART progresses from a mean of 65.3 at four weeks to 81.6 at twelve months, confirming that scaffold maturation is an ongoing biological process rather than an immediate outcome.

The most numerically detailed functional benchmark comes from knee studies, where the evidence base is larger. The Jerosch et al. post-market clinical follow-up study recorded a mean 32.4-point improvement in IKDC score — consistently above the established minimum clinically important difference of 16.7 points — sustained and slightly increased at three-year follow-up, with patients reaching a mean functional score of 80. Across the full implantation history, a complaint rate of approximately 0.06% places ChondroFiller among the better-characterised injectable scaffold devices in current clinical use.

The hip dataset is growing; it is not yet as large as the knee evidence base, but what has been published points in a consistent direction across both functional and structural outcome measures.

Assessment and next steps at London Cartilage Clinic

For patients ready to explore whether ChondroFiller is appropriate for their hip, the assessment at London Cartilage Clinic brings clinical history, imaging review, and in-room ultrasound into a single appointment. Where the findings support it, treatment can proceed in the same session — the treating specialist performs the image-guided injection directly, which is one reason the assessment and delivery are kept together rather than staged across separate visits.

Professor Paul Y.F. Lee, who leads cartilage and joint-preservation assessment at 66 Harley Street, was the first clinician in the UK to offer ChondroFiller as an injectable outpatient pathway. For patients with progressive disease, a longitudinal maintenance programme is available, structured around yearly MRI and bi-annual ChondroFiller top-ups to monitor and support the joint over time.

Patients based outside London can access the same injectable pathway through the broader MSK Doctors group, with clinics in Lincolnshire and Grantham providing an equivalent service closer to home.

To arrange an assessment, appointments can be booked via londoncartilage.com.